Richard Margolin MD is a physician-scientist trained in psychiatry and nuclear medicine with extensive academic and pharmaceutical industry experience. He is Founder and Principal Consultant at CNS Research Solutions LLC and provides clinical development guidance to biotechnology companies advancing novel therapeutics to address serious CNS disorders, especially neurodegenerative diseases. Previously, Dr. Margolin was Executive Director, Clinical Neuroscience, and Interim Alzheimer’s Disease Clinical Head, Internal Medicine Research Unit at Pfizer. Earlier, he held positions at CERESPIR, Janssen Alzheimer Immunotherapy, Schering-Plough/Merck, and i3 Research. Prior to transitioning to industry, Dr. Margolin built and directed the Division of Geriatric Psychiatry at Vanderbilt University and later led the University of Southern California’sConsultation-Liaison Psychiatry Division. Dr. Margolin received an AB degree from Harvard College magna cum laude and an MD degree from the University of California, Irvine. He has authored or co-authored 60 scientific publications and spoken widely on challenges and opportunities in drug development for neurodegenerative diseases.
Richard A Margolin, MD, Chairman
Nicholas Kanaan, PhD
Nicholas Kanaan, PhD, Associate Professor of Translational Science and Molecular Medicine, Michigan State University College of Human Medicine. Dr. Kanaan obtained a B.S. in Neuroscience, Psychology, and Sociology from Central Michigan University and Ph.D. in Neurological Sciences from Rush University Medical Center. He remained in Chicago for his postdoctoral training with Dr. Lester Binder (who generated the TBL-100 MAb) at Northwestern University. Dr. Kanaan’s laboratory researches neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease as well as the role of aging-related changes in neurodegenerative disease. Studies in the Kanaan lab focus on the molecular mechanisms underlying degenerative diseases and exploring therapeutic strategies. The Kanaan lab uses a combination of experimental approaches, including in vitro and in vivo model systems, to tackle scientific questions. Regardless of his specific basic science endeavors, one of Dr. Kanaan’s fundamental aims is to conduct research that will ultimately translate into improvements in the lives of the people affected by these devastating diseases. Dr. Kanaan has authored more than 50 peer-reviewed scientific articles.